<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04314219</url>
  </required_header>
  <id_info>
    <org_study_id>2181104</org_study_id>
    <secondary_id>Saudi FDA</secondary_id>
    <nct_id>NCT04314219</nct_id>
  </id_info>
  <brief_title>Phase III Randomized Clinical Trial Comparing Post-Transplant Cyclophosphamide (PTCy) to Standard Care (SoC) for Acute Leukemia</brief_title>
  <official_title>Phase III Randomized Clinical Trial Comparing Post-Transplant Cyclophosphamide With Calcineurin Inhibitors as GVHD Prophylaxis to Standard Care of Methotrexate and Calcineurin Inhibitors for Acute Leukemia Incorporating Patient Pharmacogenomics Profiling (PMAT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Faisal Specialist Hospital &amp; Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Faisal Specialist Hospital &amp; Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized clinical trial will evaluate two approaches of GvHD prophylaxis; the standard
      of care GVHD prophylaxis regimen (methotrexate/calcineurin inhibitors) and post-transplant
      cyclophosphamide with calcineurin inhibitors for their efficacy as a new GVHD prophylaxis
      strategy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label randomized clinical trial will be performed. Eligible patients are females and
      males, between 14 and 65 years undergoing allo-HCT for treatment of Acute Leukemia (AML or
      ALL). Patients must have a matching related peripheral blood stem cell donor. Patients from
      or referred to the KFSH&amp;RC for allogeneic transplant consideration will be offered the
      opportunity to participate in this trial.

      Treatment Description:

      Patients will be randomized on one of the arms; an intervention or a standard of care arm.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2020</start_date>
  <completion_date type="Anticipated">December 29, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 23, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GRFS (GVHD-free/relapse-free survival)</measure>
    <time_frame>One-year post-transplant</time_frame>
    <description>Defined as the non-occurrence of a grade 3-4 acute GVHD, or systemic therapy-requiring chronic GVHD, or relapse, or death during the first post-transplant year.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Graft versus Host Disease (aGVHD)</measure>
    <time_frame>100 Day post transplant</time_frame>
    <description>The probabilities of grade II-IV and III-IV acute GVHD will be determined. Acute GVHD will be graded according to Glucksberg and NIH 2014 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Graft versus Host Disease (cGVHD)</measure>
    <time_frame>One year Post-transplant</time_frame>
    <description>The cumulative incidence of systemic therapy-requiring chronic GVHD will be determined. Moderate and severe chronic GVHD will be defined per the NIH 2014 criteria.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Acute Leukemia in Remission</condition>
  <condition>Post-Transplant Cyclophosphamide</condition>
  <arm_group>
    <arm_group_label>Arm 1: Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide 50mg</intervention_name>
    <description>Cyclophosphamide as GVHD prophylaxis will be on day +3 and day +5</description>
    <arm_group_label>Arm 1: Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate as GVHD prophylaxis will be on day +1, day +3, and day +6</description>
    <arm_group_label>Arm 2: Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Acute Leukemias (AML, ALL) in morphologic complete remission with or
             without hematologic recovery

          -  Patients must have a fully matched (8/8) related donor willing to donate peripheral
             blood stem cells and must meet institutional criteria for donation

          -  Planned Myeloablative conditioning regimen

          -  Cardiac function: ejection fraction at rest ≥ 50% by MUGA or TTE

          -  Estimated creatinine clearance greater than 50 mL/minute

          -  Pulmonary function: DLCO ≥ 50% (adjusted for hemoglobin), and FVC and FEV1 ≥ 50%

          -  Liver function: total bilirubin &lt; 2x the upper limit of normal (unless elevated
             bilirubin is attributed to Gilbert's Syndrome) and ALT/AST &lt; 2.5x the upper normal
             limit

          -  Signed informed consent

        Exclusion Criteria:

          -  Karnofsky or Lansky Performance Score &lt; 70%2.

          -  Active disease

          -  Patients with uncontrolled bacterial, viral or fungal infections

          -  Presence of fluid collection (ascites, pleural or pericardial effusion) that
             interferes with methotrexate clearance or makes methotrexate use contraindicated

          -  Patients seropositive for HIV-1 or -2

          -  Patients seropositive for HTLV-I or -II

          -  Patients with active Hepatitis B or C viral replication by PCR

          -  Women who are pregnant (positive serum or urine βHCG) or breastfeeding

          -  Females with childbearing potential (FCBP) or men who have sexual contact with FCBP
             unwilling to use effective forms of birth control or abstinence for one year after
             transplantation

          -  History of uncontrolled autoimmune disease or on active treatment

          -  Patients with prior malignancies,except resected non-melanoma skin cancer or treated
             cervical carcinoma in situ; cancer treated with curative intent ≥ 5 years previously
             will be allowed; cancer treated with curative intent &lt; 5 years previously will not be
             allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Riad O El Fakih, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KFSH&amp;RC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shahrukh Hashmi, M, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>KFSH&amp;RC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahmoud D Aljurf, M, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>KFSH&amp;RC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Riad O El Fakih, MD</last_name>
    <phone>+ 966114647272</phone>
    <phone_ext>34760</phone_ext>
    <email>relfakih1@kfshrc.edu.sa</email>
  </overall_contact>
  <location>
    <facility>
      <name>King Faisal Specialist Hospital &amp; Research Center</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riad O El Fakih, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 17, 2020</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2020</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Matched Sibling Donor</keyword>
  <keyword>Allogeneic - HCT</keyword>
  <keyword>GvHD Prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

